A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT01940497 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Doxorubicin
DRUG: Docetaxel
DRUG: Paclitaxel
DRUG: Trastuzumab

Sponsor

Hoffmann-La Roche